Celldex may have a third potential (peak sales) blockbuster coming of age. The phase I study that started 18 months ago actually has a phase II component. I suspect this is one we will be hearing a lot about this year. Another shot on goal and Celldex's precision-targetted molecules with companion diagnostic approach is winning time and time again. That means there are years and years of growth ahead as new targets, molecules and diagnostics are brought forward. The future look very bright for Celldex stakeholders!